AbbVie clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-22
What changed in the last 30 days
31 trials changed in the last 30 days: 0 stopped, 6 with notable changes, 25 with minor changes only.
- Minor: Upadacitinib · Alopecia Areata Trial sites expanded: 13 → 22 locations
- Minor: NOA HYDRATION Injectable Gel for the Improvement of Skin Quality Including Attributes Such as Skin Smoothness Trial sites expanded: 4 → 7 locations
- Minor: Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment · Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Trial sites expanded: 3 → 9 locations
- Minor: Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 · Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA) Trial sites expanded: 13 → 17 locations
- Minor: IMGN632 · Untreated BPDCN and Relapsed/Refractory BPDCN Trial completed
- Minor: REVIVAL · Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine · Acute Myeloid Leukemia (AML) Trial sites expanded: 36 → 40 locations
- Minor: AndroMETa-CRC · Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil · Refractory Metastatic Colorectal Cancer Trial sites expanded: 87 → 91 locations
- Minor: Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA · Moderate to Severe Upper Facial Lines Trial sites expanded: 21 → 24 locations
- Minor: Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor · Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations Trial sites expanded: 127 → 131 locations
- Minor: 3112 Ped BPD · Change in Disease Activity and Adverse Events (AEs) With Cariprazine · Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder Enrollment reduced: 380 → 338 participants
- Notable: Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies · Relapsed or Refractory Multiple Myeloma Recruitment opened
- Minor: H25-878 ORCHES · Practical ExperienceS of Treatment With Foslevodopa/foScaRbidopa in Advanced Parkinson's Disease Trial completed
- Minor: AAVIATE · RGX-314 Gene Therapy Administered in the Suprachoroidal Space · Neovascular Age-Related Macular Degeneration (nAMD) Primary completion date changed from estimate of Aug 2026 to Oct 13, 2026
- Minor: ALTITUDE® · RGX-314 Gene Therapy Administered in the Suprachoroidal Space · Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME) Trial completed
- Minor: How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants Trial completed
- Minor: Step-Up HS · Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent · Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy Primary completion pushed from Mar 2028 to Aug 2028
- Minor: Change in Disease Activity and Adverse Events in Adolescent and Adult · Moderate to Severe Active Crohn's Disease (CD) in Japan Trial completed
- Notable: Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) · Relapsed or Refractory Multiple Myeloma Primary endpoint(s) modified
- Notable: PUCCINI · Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease Primary endpoint(s) modified
- Notable: Targeted Therapies · Active Psoriatic Arthritis Primary and study completion dates pushed to Aug 2029
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New trial filings, last 30 days
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-11-13 | NCT07935564 A Study to Assess the Adverse Events and How Oral ABBV-1606 Moves Through the Body of… | Phase 1 | Not Yet Recruiting |
| 2026-11-12 | NCT07933211 A Study to Evaluate the Safety and Efficacy (How Well the Study Treatment Works) of… | Phase 2/3 | Not Yet Recruiting |
| 2026-11-12 | NCT07933497 M4 Receptor PET Radioligand Validation Study in Healthy Adults | Early Phase 1 | Not Yet Recruiting |
| 2026-11-12 | NCT07933536 A Study to Assess Targeted Therapies for Treatment of Adults With Moderate to Severe… | Phase 2 | Not Yet Recruiting |
| 2026-11-09 | NCT07925983 A Study to Assess How Intravenous and Subcutaneous Administrations of Trosunilimab Move… | Phase 1 | Recruiting |
| 2026-10-29 | NCT07904754 Platform Study of Targeted Therapies for Adults With Moderately to Severely Active… | Phase 2 | Not Yet Recruiting |
| 2026-10-27 | NCT07896421 Real-World Study of Mirvetuximab Soravtansine in Adult Participants With… | Recruiting | |
| 2026-10-27 | NCT07896434 A Study to Learn How Effective, Safe, and Tolerable Upadacitinib is for Young… | Phase 3 | Not Yet Recruiting |
| 2026-10-26 | NCT07895043 A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV)… | Phase 2 | Not Yet Recruiting |
| 2026-10-26 | NCT07895056 A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV)… | Phase 2 | Not Yet Recruiting |
Active trials by phase
| Early Phase 1 | 1 | |
| Phase 1 | 51 | |
| Phase 1/2 | 9 | |
| Phase 2 | 52 | |
| Phase 2/3 | 11 | |
| Phase 3 | 63 | |
| Phase 4 | 4 |
Not charted: 48 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials, top 10 of 52
Lung Cancer (21) · Leukemia (20) · Multiple Myeloma (17) · Non-Small Cell Lung Cancer (NSCLC) (16) · Ovarian Cancer (16) · Crohn's Disease (14) · Migraine (13) · Ulcerative Colitis (13) · Psoriasis (12) · Chronic Lymphocytic Leukemia (CLL) (11)
Get alerts when AbbVie's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.